Accepted for/Published in: JMIR Formative Research
Date Submitted: Jan 4, 2024
Date Accepted: Jun 17, 2024
Identifying barriers to the adoption of digital contact tracing applications in England: a qualitative study
ABSTRACT
Background:
The NHS COVID-19 application was England's response to limit the spread of COVID-19. At the time of the COVID-19 pandemic and since many questions have been raised regarding the effectiveness of this application and of if digital contact tracing applications have a use in future pandemics.
Objective:
The objective of this study was to explore the key barriers to the adoption of digital contact tracing apps (DCTAs) in England during the COVID-19 pandemic and use the learnings from this to aid the adoption of DCTAs in the future.
Methods:
Semi-structured virtual video interviews conducted with professionals in the public health and digital health fields, clinicians, health care law and health executives. Initial use of maximum variation sampling combined with snowball sampling approach ensured diversity within the cohort of interviewees. Interview transcripts were then analysed using Braun and Clarke’s Six Steps for Thematic Analysis.
Results:
Interviewees shared the sentiment of privacy concerns due to poor communication and a lack of transparency from the government over the NHS COVID-19 app, thus leading to a lack of trust in the app. The inaccessibility to technology, digital illiteracy and user accessibility were raised as another obstacle to app adoption. The lack of social support integration within the DCTA and delayed app notification period also contributed to the poor adoption rates.
Conclusions:
To increase the adoption of digital contact tracing apps in the future, the barriers of privacy concerns, communication from the government, digital illiteracy, access to technology and integration of support networks within the apps must be addressed and overcome. Should there be a necessity to contact trace nationwide in the future, DCTAs should be already prepared, in advance, to be launched and rolled out to the whole population. Clinical Trial: N/A
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.